F-star Therapeutics, Inc. (FSTX)

Overview

F-star Therapeutics, Inc. is a pioneering clinical-stage biopharmaceutical company focused on the development of tetravalent bispecific antibodies aimed at addressing cancer, with a strong emphasis on immuno-oncology. The firm was established in 2002 and is headquartered in Cambridge, United Kingdom. F-star is committed to advancing innovative therapeutics to improve patient outcomes in cancer treatment. Its primary investigational agent, FS118, has progressed to a Phase 2 proof-of-concept trial, specifically assessing its effectiveness in patients with head and neck cancer who have shown resistance to conventional PD-1/PD-L1 therapies. In addition, the company is advancing its research pipeline, developing multiple other candidates targeting diverse malignancies.

Products and Services

• FS118: Currently in a Phase 2 clinical trial, FS118 is designed to evaluate its efficacy in treating head and neck cancer in patients who have developed resistance to PD-1/PD-L1 therapies. This investigational product aims to provide a novel treatment option for a patient population that has limited alternatives.
• FS222: This bispecific antibody is undergoing an initial Phase 1 human clinical study to assess its safety and early efficacy. FS222 simultaneously targets the costimulatory CD137 receptor and the inhibitory PD-L1 ligand, offering a dual mechanism to enhance immune response against cancer cells.
• FS120: Another candidate in the F-star portfolio, FS120 is currently in Phase 1 clinical evaluation. This drug is being developed to provide new therapeutic options for patients with advanced malignancies, focusing on expanding treatment choices and improving outcomes.
• SB 11285: Similarly in Phase 1 clinical evaluation, SB 11285 targets advanced malignancies with the aim of addressing significant unmet medical needs in this patient cohort. The continuous evolution of this drug candidate reflects F-star's commitment to innovative therapies for complex conditions.